There are 2789 resources available
630P - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Presenter: Christian Gratzke
Session: ePoster Display
631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
Presenter: Alejo Rodriguez-Vida
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
485P - A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study
Presenter: YONG LI
Session: ePoster Display
799P - Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
Presenter: Wei Wei
Session: ePoster Display
800P - Tailoring adjuvant treatments in high-risk early stage endometrial cancer: Clinical outcomes of sequential chemoradiation in a real-word scenario
Presenter: Marco de Scordilli
Session: ePoster Display
801P - Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
Presenter: Emeline Colomba
Session: ePoster Display
802P - A machine learning-based framework for efficacy and safety analysis of PD-1PD-L1 inhibitor application in gynaecological cancer on incomplete post-marketing surveillance dataset
Presenter: xiaomei Liu
Session: ePoster Display